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Abstract
As an inhibitor of cyclin-dependent kinases, p16
INK4A is an important tumour suppressor and inducer of cellular senescence
that is often inactivated during the development of cancer by promoter DNA methylation. Using newly established
lymphoblastoid cell lines (LCLs) expressing a conditional EBNA3C from recombinant EBV, we demonstrate that EBNA3C
inactivation initiates chromatin remodelling that resets the epigenetic status of p16
INK4A to permit transcriptional activation:
the polycomb-associated repressive H3K27me3 histone modification is substantially reduced, while the activation-related
mark H3K4me3 is modestly increased. Activation of EBNA3C reverses the distribution of these epigenetic marks, represses
p16
INK4A transcription and allows proliferation. LCLs lacking EBNA3A express relatively high levels of p16
INK4A and have a
similar pattern of histone modifications on p16
INK4A as produced by the inactivation of EBNA3C. Since binding to the co-
repressor of transcription CtBP has been linked to the oncogenic activity of EBNA3A and EBNA3C, we established LCLs with
recombinant viruses encoding EBNA3A- and/or EBNA3C-mutants that no longer bind CtBP. These novel LCLs have revealed
that the chromatin remodelling and epigenetic repression of p16
INK4A requires the interaction of both EBNA3A and EBNA3C
with CtBP. The repression of p16
INK4A by latent EBV will not only overcome senescence in infected B cells, but may also pave
the way for p16
INK4A DNA methylation during B cell lymphomagenesis.
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Introduction
In vitro, EBV can very efficiently induce the activation and
continuous proliferation of resting human B lymphocytes. The
resulting lymphoblastoid cell lines (LCLs) carry the viral genome
as extra-chromosomal episomes and express only nine ‘latent’
EBV proteins. There are six nuclear antigens (EBNAs 1, 2, 3A, 3B,
3C & LP), three membrane associated proteins (LMP1, LMP2A &
2B) and in addition several untranslated RNA species. Together
these factors activate the quiescent B cells and sustain their
proliferation while maintaining the viral episome in its extra-
chromosomal state (reviewed in [1]). Current data on the
persistence of EBV in humans are consistent with the viral
genome residing long-term in the resting memory B cell
compartment. This occurs in at least of 90% of the world’s
population. However, to establish persistence EBV generally
infects resting (naı ¨ve) B cells in Waldeyer’s ring of the oropharynx
and drives these to proliferate as activated B-blasts. This transient
expansion of an infected B-blast population is generally accom-
panied by migration into germinal centres and differentiation to
become centroblasts and centrocytes and finally resting memory B
cells. The precise series of events that the EBV-positive B cells
undergo to reach the memory compartment is unknown, but it
appears to involve the regulated, sequential silencing of EBV genes
encoding latency-associated proteins [2,3].
Although infection is generally asymptomatic, EBV can be the
causative agent in the benign self-limiting lymphoproliferation,
infectious mononucleosis (IM). Uncontrolled proliferation of
latently infected B cells in the immunocompromised may result
in a chronic form of IM, a chronic polyclonal B-lymphoprolifer-
ative disorder called post-transplant lymphoproliferative disease
(PTLD) or rarely the development of malignant lymphoma.
Individuals co-infected with malaria (mainly children) or HIV
(mainly adults) may be at increased risk of developing EBV-
associated B cell lymphomas, including Burkitt’s lymphoma (BL)
and diffuse large B cell lymphoma [4].
EBNA3A, EBNA3B and EBNA3C are considered to comprise a
family which probably arose in primate gamma-herpesvirus
evolution by a series of gene duplication events since they have
the same gene structure (ie a short 59 coding exon and a long 39
coding exon), are arranged in tandem in the EBV genome and
share limited but significant amino acid sequence homology.
EBNA3 transcripts are alternatively spliced from very long
mRNAs generally initiated at the Cp latency promoter and LCLs
have only a few copies of these transcripts per cell, suggesting their
expression is very tightly regulated and the turnover of the
EBNA3s is slow [1,5]. Although they are related and the three
proteins have limited homology, there is nothing to suggest that
they have extensively redundant functions. Genetic studies using
recombinant viruses originally indicated that EBNA3A and
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immortalisation of B cells, whereas EBNA3B is dispensable [6,7].
However, under the appropriate conditions, with feeder cells
present, it has been possible to establish EBNA3A-negative LCLs
([8]; our unpublished data).
Each EBNA3 protein binds to the cellular DNA-binding factor
RBP-JK (also known as CBF1). This is the same protein that binds
to, and targets to DNA, the EBV transactivator EBNA2 and the
NOTCH-IC effector of the NOTCH signalling pathway.
EBNA3A, EBNA3B and EBNA3C can repress Cp reporter
plasmids and plasmids containing multiple RBP-JK/CBF1
binding sites derived from Cp ([9,10,11,12]; P. Young and MJA,
unpublished data). Since Cp is generally the promoter for all
EBNA mRNA initiation in LCL cells, the EBNA3 proteins
probably contribute to a negative auto-regulatory loop. In addition
all three EBNA3s exhibit robust repressor activity when targeted
directly to DNA by fusion with the DNA-binding domain of Gal4
and they all interact with one or more cellular factor(s) involved in
transcriptional repression or silencing; these include histone
deacetylases (HDACs) and CtBP ([11,12,13,14,15,16,17]; P.
Young and MJA, unpublished data).
CtBP (C-terminal binding protein) was initially discovered as a
cellular factor interacting with the C-terminus of adenovirus E1A
oncoprotein andsubsequentlyidentifiedasoneofa highlyconserved
family of co-repressors of transcription (reviewed in [18]). Most of
the factors that bind to CtBP and negatively regulate transcription
contain at least one conserved Pro-Leu-Asp-Leu-Ser (‘‘PLDLS’’)
CtBP-interaction domain (or close variant) that is necessary and
probably sufficient for the interaction. CtBP-containing complexes
can coordinate biochemical and enzymatic events that convert
transcriptionally active chromatin directly to a repressive or silent
state ([19,20]). Moreover there is also good evidence that CtBP is
involved in the regulation of cell proliferation since it has been
shown that CtBP forms a link between human polycomb group
(PcG) proteins and pRb [21] and that CtBP and PcG complexes
both regulate elements in the CDKN2A locus [22,23].
EBNA3A and EBNA3C each bind to CtBP in vitro and in vivo but
this binding correlates only partially with their ability to repress
transcription when targeted to DNA in transient reporter assays.
However, the interaction correlates extremely well with their ability
to behave as cooperating nuclear oncogenes when introduced into
primary rodent fibroblasts with oncogenic Ha-RAS [16,17,24].
Since in this type of assay, the oncogene Ha-RAS alone triggers exit
from the cell cycle and premature senescence via the induction of
the p16
INK4A and/or p19
ARF proteins encoded by the CDKN2A
locus [23,25], this suggests that EBNA3A and EBNA3C can each
rescue primary fibroblasts from growth arrest and senescence.
Further evidence that EBNA3C deregulates the cell cycle came
with the demonstration that when over-expressed it overcomes a
mitotic metaphase checkpoint and induces polyploidy and multi-
nucleation, eventually leading to cell death [26]. However, the
molecular details of its action in mitosis have remained elusive. A
reported interaction with CHK2 suggests that it could have a role in
the transition from G2 to mitosis, but this has not yet been proven
[27] and although it has been reported that EBNA3C may repress
the transcription of the mitotic regulator BUBR1 in one B cell line,
this has not been extended to LCLs [28]. Several recent reports
indicate that EBNA3C can also directly associate with multiple
other factors involved in the regulation of cell cycle progression
and/or the G1/S checkpoint. These include Cyclin A; the ubiquitin
ligaseSCF
SKP2; thetumoursuppressor pRb; the oncoproteinMYC;
MDM2 in a complex with p53 and p53 alone [29,30,31,32,33,34].
It remains to be determined if these interactions occur in infected B
cells and whether they are functionally significant.
The most direct and compelling evidence that EBNA3C
modulates the cell cycle during EBV-mediated transformation of
B cells into LCLs comes from Maruo and colleagues. Using a
recombinant Akata EBV made conditional for EBNA3C function
by fusing EBNA3C with a modified oestrogen receptor, they
revealed that EBNA3C represses expression of the cyclin-
dependent kinase inhibitor p16
INK4A in LCLs. Removing the
inducer of EBNA3C activity (4-hydroxytamoxifen) from the
culture medium results in an accumulation of both p16
INK4A
mRNA and protein and in reduced cell proliferation [35].
EBNA3A also cooperates with Ha-RAS in the transformation
and immortalization of REFs and there is again a remarkably good
correlation between EBNA3A binding to CtBP and its ability to
cooperate with oncogenic ras [17]. Furthermore, a 4-hydroxyta-
moxifen-dependent LCL conditional for EBNA3A function showed
thatinthe absenceofEBNA3A,cellproliferationgraduallydeclines.
Although it was not indicated whether this involved regulation of
the CDKN2A locus [36], a more recent reportof a microarrayscreen
has indicated that repression of p16
INK4A transcription in LCLs is
associated with EBNA3A expression [8].
We recently demonstrated that EBV represses transcription of
the gene encoding the pro-apoptotic BCL-2-related family
member BIM [37,38]. The repression of BIM transcription
initially involves a polycomb repressive complex, PRC2, where
the histone methyltransferase EZH2, which together with SUZ12
and EED, is responsible for establishing the epigenetic modifica-
tion H3K27me3 (tri-methylation of lysine 27 on histone H3)
(reviewed in [39,40]). H3K27 methylation of BIM may then be
followed by DNA methylation of sites within the CpG-island
flanking the BIM transcriptional initiation site ([38] and our
unpublished data). Since EBNA3A and EBNA3C are necessary for
the chromatin remodelling and epigenetic repression of BIM, here
we have examined the p16
INK4A locus and the roles EBNA3A and
EBNA3C play in regulating its epigenetic status.
Materials and Methods
Generation of recombinant EBV-BACs
An EBNA3C-HT fusion protein (3CHT) in the B95-8
background was constructed with the same linking sequence and
Author Summary
We previously showed that two Epstein-Barr virus latency-
associated proteins—EBNA3A and EBNA3C—contribute to
enhanced B cell survival by inhibiting the expression of the
death-inducing protein BIM. This repression involves
remodelling of the BIM gene promoter by polycomb
proteins and DNA methylation within an unusually large
CpG-island that flanks the transcription initiation site. Here
we show that the same two proteins, EBNA3A and
EBNA3C, functionally cooperate in the polycomb-mediated
chromatin remodelling of another tumour suppressor
gene, p16
INK4A, that encodes a cyclin-dependent kinase
inhibitor capable of blocking cell proliferation. Both EBV
proteins can bind the highly conserved co-repressor of
transcription CtBP, and these interactions appear to be
required for the efficient repression of p16
INK4A. Thus by
utilising the polycomb system to induce the heritable
repression of two major tumour suppressor genes—one
that induces cell death (BIM) and one that induces growth
arrest (p16
INK4A)—EBV profoundly alters latently infected B
cells and their progeny, making them significantly more
prone to malignant transformation.
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previously been described in the Akata background [35]. The
connection between the 3C and HT is a single proline residue
between the last amino acid of EBNA3C and amino acid 281 of
the murine estrogen receptor alpha (modified by G525R to make
it 4-hydroxytamoxifen-specific. This fusion was recombined into
the B95-8 bacterial artificial chromosome (BAC) [41] using
previously described methods [37,42] to produce two independent
BACs containing 3CHT (A and C).
A set of CtBP-binding-mutant viruses were generated in which
the EBNA3A and/or EBNA3C binding site(s) for CtBP were
replaced with previously characterised mutations that lack the
ability to bind CtBP [16,17]. This was achieved by a sequential set
of recombinations, initially mutating the pair of CtBP binding sites
in EBNA3A (to generate the 3A
CtBP mutant). The EBNA3C
binding site for CtBP in this was then mutated to create a virus
genome lacking all CtBP binding sites among the EBNA3s
(E3
CtBP). Then the EBNA3A mutant sequence was replaced with
wild-type sequence, leaving only the EBNA3C sequence as mutant
(3C
CtBP) and finally the EBNA3C sequence was reverted to wild-
type sequence, generating the CtBP revertant (rev
CtBP).
Cell culture
Established LCLs were cultured in RPMI-1640 medium
(Invitrogen) supplemented with 10% fetal calf serum, penicillin
and streptomycin. LCL 3CHT were cultured with addition of
400nM of 4-hydroxytamoxifen (HT, Sigma). After the infection of
primary B cells, LCLs were grown to a volume and density
suitable for freezing multiple aliquots (typically about 60ml at a
density of 3610
5 cells/ml or greater). This took 4–8 weeks for
WT-EBV, revertant and 3CHT LCLs and 6–12 weeks for the
EBNA3A and CtBP mutant LCLs.
Cells recovered from liquid nitrogen were cultured for about 10
days (with HT if necessary) before the start of any experiment. At
the end of an experiment the cells were discarded. Twenty-four
hours before any experimental treatment, cells were seeded at a
density of 2.5610
5 cells/ml.
Infection of 1u B cells with recombinant EBV
Virus was produced by transfection of recombinant BACs into
HEK293 cells [(ATCC, CRL-1573), a kind gift of Claire
Shannon-Lowe, University of Birmingham] and selection of clonal
Hygromycin B-resistant cell lines, which were screened for
integrity of EBV genome by episome rescue and pulsed-field gel
analysis of BAC restriction digests (not shown). Infectious virus was
produced by the transfection of EBV-BAC-containing 293 cells
with BZLF1 and BALF4 expression constructs [43], and after 4
days, supernatant was filtered through 0.45 mm filters. Virus titre
was assessed by infection of Raji cells and counting green cells on
an inverted fluorescent microscope after enhancement of GFP
expression by overnight treatment with 5 nM TPA and 1.25 mM
sodium butyrate. Virus titres were typically in the range of 50 to
250 raji green units (rgu) per microlitre of tissue culture
supernatant.
B-cells for generation of LCL-3CHT-A and -C and EBNA3A-
knockout LCLs (and for limiting dilution experiments – see below)
were isolated from buffy coat residues (UK blood transfusion
services) by centrifugation over ficoll. CtBP mutant LCLs and
3CHT-LCL B, D and E (described herein) were generated by
infection of PBLs isolated from donated EBV-seronegative blood
(a kind gift of Ingo Johannessen, University of Edinburgh). Three
donors were used (D1, D2 and D3). 3CHT-LCL B, D and E were
made by infection of in blood from donors 1, 3 and 2 respectively
with EBV-3CHT-A virus. Essentially, between 50 ml and 1 ml of
virus was added to 10
6 PBLs (typically 2–8% of which are B-cells
by FACS for CD20; not shown) in a well of a 24 well plate, and
cultured initially in RPMI supplemented with 15% FCS,
supplemented with Cyclosporine A (500 ng/ml) for the first 2–3
weeks. Once LCLs had grown out into large culture volumes, the
FCS level in the medium was reduced to 10%.
Limiting dilution and cell growth assays
Virus stocks were diluted to 2610
4 Raji green units (rgu) per ml
in RPMI supplemented with 10% FCS, and ten-fold serial
dilutions used to generate virus concentrations down to 0.2 rgu/
ml. The virus was added to an equal volume of PBLs at 2610
6
cells per ml, and 1 ml was seeded per well in a 24 well plates. Two
virus preparations from independent 293 cell producer lines were
used for each virus mutant, and 6 wells for each virus
concentration. 24 wells with no virus were used to control for
spontaneous immortalisation of B-cells. After a week, the culture
volume was increased to 2 ml and half the culture volume was
replaced weekly thereafter. For the first 2 weeks, the medium was
supplemented with cyclosporine A (500 ng/ml). Cell growth was
monitored and wells were scored positive or negative after 40 days,
based on the presence of clumps of cells characteristic of LCLs. To
assess growth rate of CtBP-mutant LCLs, 5610
4 cells per ml of
cells were seeded in 10 ml in a flask. 0.5 ml was removed every
day and live cells (by trypan blue staining to exclude dead cells)
were counted on a haemocytometer.
Flow cytometry
To analyse cell cycle distribution, 2610
6 LCL cells were fixed in
80% ethanol, incubated in PI solution [PBS containing 18 mg/ml
propidium iodide (PI) and 8 mg/ml RNase A (Sigma Aldrich)] at
4uC for 1 h before flow cytometric analysis. To quantify cells in S
phase, cells were pulsed with 10 mM 5-bromo-29-deoxyuridine
(BrdU) (Sigma Aldrich) for 1 h at 37uC, harvested immediately
after the pulse, fixed in 80% ethanol and co-stained with FITC-
conjugated anti-BrdU mAb (Becton Dickinson) for 1 h at room
temperature and PI solution for 1 h at 37uC.
Western immunoblotting
Western blotting was performed essentially as described
previously [16]. Briefly, proteins extracted using RIPA buffer, or
in some cases whole cell lysates were resolved by sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) and
transferred to Protran nitrocellulose membranes (Schleicher and
Schuell Bioscience, Dassel, Germany). Membranes were blocked
with 5% milk powder in PBS/0.05% Tween 20, probed with
appropriate primary and HRP-conjugated secondary antibodies.
ECL kit (Amersham Biosciences, Chalfont St Giles, UK) was used
for visualization. Following primary antibodies were used: mouse
monoclonal anti-c-tubulin (Sigma, T6557), sheep polyclonal anti-
EBNA3A (Exalpha, USA), mouse monoclonal anti-EBNA3C
(A10, kind gift from Prof. Martin Rowe, University of Birming-
ham), mouse monoclonal phospho-independent anti-Rb (BD
Pharmingen, 554136), rabbit polyclonal anti-phospho-Rb (Ser
807–811) (Cell Signaling, 9308), mouse monoclonal anti-E2F1
(Millipore, mixed clones cKH20 and KH95, 05-379), mouse
monoclonal anti-p16
INK4A (clone JC8, kind gift from Dr Gordon
Peters, Cancer Research UK), rabbit polyclonal anti-p130 (Santa-
Cruz, c-20, sc-317), rabbit polyclonal anti-p107 (Santa Cruz, c-18,
sc-138), mouse monoclonal anti-EBNA2 (clone PE2, Dako), mouse
monoclonal anti-LMP1 (clone CS1-4, Dako), mouse monoclonal
anti-EBNA-LP (clone JF186, gift of Paul Farrell), rat monoclonal
anti-LMP2A (clone 14B7, AbCam 59026), rabbit polyclonal anti-
CtBP [16] and rat monoclonal anti-EBNA3B (clone 6C9,
Epigenetic Repression of p16
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mRNA and Quantitative real time PCR (Q RT-PCR)
For Q RT-PCR, RNA was extracted from approximately
5610
6 cells for each cell line using the RNeasy mini kit from
Qiagen and following the manufacturer’s instructions. One
microgram of each RNA sample was reverse-transcribed using
SuperScript III First-Strand Synthesis Supermix for qRT-PCR
(Invitrogen). Between 0.5–1% of cDNA product (equivalent to 5–
10 ng RNA) was used per qPCR reaction. qPCR was performed
on an ABI 7900HT real-time PCR machine using Platinum Sybr
Green qPCR SuperMix UDG kit (Invitrogen). The cycling
conditions were 95uC for 20 sec, followed by 40 cycles of 1 sec
at 95uC, 20 sec at 60uC on a fast block. Dissociation curve analysis
was performed during each run to confirm absence of non-specific
products. Sequences of the assays used are listed in Table S1.
Standard curves, used to standardise amplification efficiency,
were produced by six 5-fold serial dilutions of a mixture containing
all cDNA samples used. Results were analyzed with qbase
PLUS
software (Biogazelle, Ghent, Netherlands). Precise normalization
was achieved using internal average control calculated from the
controls (housekeeping genes – bold in Table S1) with highest
stability rating (usually ALAS1 and GNB2L1). The calculated
errors in the graphs are the standard errors from three replicate
qPCR reactions for each mRNA.
Chromatin immunoprecipitations (ChIP)
Chromatin immunoprecipitations for methylated histone H3
were performed essentially as described previously [38]. Precipitat-
ed DNA was cleaned using QIAquick Gel Extraction Kit (Qiagen)
and was assayed by qPCR. Input DNA Ct was adjusted from the
5% used inthe qPCR to 100% equivalent by subtracting4.32 (Log2
of 20) cycles. ‘Percent input’ precipitated was then calculated by
10062
‘ (Ct adjusted input – Ct IP). Non-specific background was
estimated by precipitation with IgG (data not shown since all values
were below 0.03% of input). The error bars represent standard
deviations from triplicate pPCR reactions for both input and IP.
Sequences of the primers used in these assays are listed in Table S2.
Results
Inactivation of EBNA3C leads to proliferative arrest of LCL
3CHT that can be reversed by re-adding HT
In order to examine in detail the regulation of p16
INK4A and cell
proliferation by EBV, initially a recombinant EBV encoding a
conditional EBNA3C was constructed. We employed the B95.8
EBV-BAC system used previously to generate EBNA3-knockout
(KO) viruses and the design of fusion proteins described by Maruo
and colleagues for fusing the carboxyl-terminus of EBNA3C to a
modified estrogen receptor [35,37]. EBNA3C fused to this estrogen
receptor is dependent on 4-hydroxytamoxifen (HT) in the culture
medium for its function and stability. Two independently generated
viruses encoding the EBNA3C-HT-fusion (3CHT) were used to
establish multiple lymphoblastoid cell lines (called LCL 3CHT).
LCL 3CHT – with one notable exception described below –
required HT in the culture medium for their proliferation. When
HT was removed, after 3–7 days there was a dramatic reduction in
the amount of EBNA3C detected by western blotting (for a
representative example see Figure 1). This reduced expression is
probably because the inactivated fusion binds to heat shock
proteins and is targeted for proteasome-mediated degradation and
is consistent with the behaviour of the equivalent fusion in the
Akata strain EBV [35]. The LCLs were validated further by
western blot analyses probing for each of the EBV latent proteins.
As was previously reported in Akata, no consistent differences in
steady state levels were seen. In the absence of HT a very slight
increase in LMP1 was sometimes observed – this was also reported
previously (Figure S1; [35] and data not shown).
In order to confirm that inactivation of EBNA3C compromises
cellular DNA synthesis, BrdU incorporation was assessed. Two
LCL 3CHT (-A & -C) cells were cultured with HT, then for 14 or
33 days after HT had been removed from the culture medium.
Cells were then pulsed for 1 hour with BrdU, harvested, fixed and
stained with anti-BrdU-FITC and propidium iodide. The cells
were analysed by flow cytometry (see for example Figure 2A). In
both LCL 3CHT, BrdU incorporation after 14 days without HT
was reduced to about 40% of that in similar control cells cultured
with HT and after 33 days the reduction in the proportion of cells
entering S phase was even more profound (Figure 2B).
To establish whether the growth arrest could be reversed upon
reactivation of EBNA3C-HT, HT was re-added after 14 or 33 days
growth in its absence. Surprisingly, although the levels of EBNA3C-
HT were re-established quite rapidly (within about 24 hours: see
Figure 1), there was a significant delay before BrdU incorporation
matched that of the controls. These cells clearly do not behave like a
synchronised G1/S-arrested population released into S phase.
WhenHTwasre-addedafter14dayswithout HT,ittook12daysto
return to the level of proliferation seen in control cells (Figure 2C).
When the HT was re-added after 33 days without HT, the period
required to achieve full proliferation was extended to 16 days
(Figure 2D). Since the restoration of cell proliferation after
reactivation of EBNA3C is dependent on the time elapsed without
functional EBNA3C, it is possible that a subpopulation of cells is
being driven into in a state of irreversible arrest similar to
senescence. These would be refractory to further pro-proliferative
signals from EBNA3C and they would gradually accumulate.
Alternatively there may be an intrinsic delay associated with the
molecular processes necessary to re-induce cell cycle progression in
individual arrested cells. It should be noted that, although viable,
these non-proliferating cells did not stain positive for the operational
mark of senescence b-galactosidase (data not shown).
Proliferation of LCL 3CHT correlates with the regulation
of p16
INK4A expression
Maruo and colleagues described how in the absence of functional
EBNA3C, the cyclin-dependent kinase inhibitor p16
INK4A accu-
Figure 1. EBNA3C inactivation and reactivation in LCL 3CHT.
Cells that had been grown in culture medium containing HT were
washed and re-suspended in medium with HT omitted. After culturing
for the number of days indicated, protein extracts were western blotted
and probed with an anti-EBNA3C MAb to reveal EBNA3C-HT. After 17
days some cells were transferred to medium containing HT and after 1,
5 or 8 days samples were again taken for western blotting. The western
blot was re-probed with anti-c-tubulin to ensure equal loading of the
proteins.
doi:10.1371/journal.ppat.1000951.g001
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p16
INK4A levels occur in the B95.8-derived LCL 3CHT, and
determinewhethertheresponsetoEBNA3Creactivationcorrelated
with (and could account for) the reduction in p16
INK4A expression
and the changes in proliferation of LCL 3CHT described above.
The DNA sequence of the unique first exon of p16
INK4A is GC
rich and is predicted to have extensive secondary structure under
the conditions used for qPCR (based on DNA sequence analysis
using Visual OMP). A quantitative RT-PCR assay specific for
p16
INK4A transcripts, which detects the amplicon located within the
unique first exon of p16
INK4A (Table S1), is quantitative only in the
presence of large amounts of template. Therefore, a second assay
that quantifies an amplicon located within the second and third
exon shared by p16
INK4A and p14
ARF was designed (CDKN2A assay;
Table S1), which is quantitative over a 5-log range of template
concentration. These assays were used to show that the regulation
of p16
INK4A in B95.8-BAC LCL 3CHT is reversible (Figure 3).
After 14 days in culture in the absence of HT, there was a 2-2.5-
Figure 2. Proliferation of LCL 3CHT after inactivation and reactivation of EBNA3C. (A) LCL 3CHT cells were cultured either with HT (+HT) or
for 33 days after the removal of HT (-HT) from the growth medium. Cells were pulsed for 1 hour with BrdU, harvested, fixed and stained with anti-
BrdU-FITC and propidium iodide. The cells were analysed by flow cytometry. The gated BrdU-positive population is reduced in the absence of HT. (B)
Two LCL 3CHT (-A and -C) generated from independent 3CHT-BACs using PBL from a single donor were analysed as in (A) after 14 and 33 days
without HT. Histograms show BrdU incorporation relative to the control, cycling population. The control (ctrl) was a proliferating population of LCL
3CHT grown in medium with HT. (C) LCLs 3CHT-A and -C were cultured for 14 days in the absence of HT (0) and BrdU-incorporation was assayed as in
(A). The incorporation of BrdU was also assayed as above after 4, 7 and 12 days after re-adding HT. (D) A similar experiment was performed on cells
cultured without HT for 33 days.
doi:10.1371/journal.ppat.1000951.g002
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population. After re-adding HT into the medium, CDKN2A
transcripts gradually decreased over the next 12 days (Figure 3A).
This result was confirmed with the p16
INK4A-specific assay
(Figure 3B). Extending the period of culture in the absence of
HT to 33 days resulted in a 3 to 5-fold increase in the level of
CDKN2A transcripts. After re-adding HT to the medium, CDKN2A
transcripts gradually decreased to the levels found in an actively
proliferating culture, but it seemed to require at least 16 days
(Figure 3C). This was also consistent with the results using the
p16
INK4A-specific primer set (Figure 3D).
Echoing the transcript data, p16
INK4A protein expression was
gradually reduced after reactivation of EBNA3C in LCL 3CHT
(Figure 3E). We conclude that regulation of p16
INK4A expression
in LCL 3CHT undergoing changes in proliferation seems to be
exclusively or at least predominantly at the level of transcription as
has been previously shown in various types of cell, including LCLs
[23,35].
Taken together, the data confirm that p16
INK4A accumulates in
LCL 3CHT cultured without HT and this inversely correlates
with the proportion of cells entering S phase. The data show for
the first time that when EBNA3C is reactivated by the re-addition
of HT to the culture medium, the reverse occurs and the
correlation between EBNA3C activity, p16
INK4A transcription and
proliferation holds true.
Inactivation of EBNA3C leads to dephosphorylation of
the retinoblastoma protein (Rb), reduced expression of
p107 and an increase in p130; activation of EBNA3C
reverses these processes
In order to determine the consequences of p16
INK4A accumula-
tion on the rest of the Rb-axis in the absence of functional EBNA3C,
LCL 3CHT were cultured with HT (controls) and without HT for
14and33days.Subsequently,HTwasre-addedonday14oronday
33. In arrested cells, Rb became hypophosphorylated (as revealed by
both pan-specific and phospho-specific anti-Rb antibodies); as the
arrest intensified after extended time without HT, reduced
phosphorylation was accompanied by a slight reduction in the
expression of Rb (Figures 4A and B). Simultaneously the Rb-related
p130 protein accumulated and the amount of p107 was reduced
(Figure 4B, annotated 014 and 033). This was particularly apparent
after 33 days. Consistent with the data showing recovery after re-
addition of HT and the reconstitution of functional EBNA3C, Rb
was gradually re-phosphorylated and up-regulated (Figure 4B);
concomitantly, expression of p130 decreased as cells entered the
proliferation cycle, and p107 expression increased.
Regulation of H3K27me3 and H3K4me3 across the
p16
INK4A locus in LCL 3CHT requires EBNA3C
The repression of p16
INK4A by PcG silencing complexes adding
H3K27me3 marks to chromatin has been well characterized in
primary fibroblasts. In pre-senescent proliferating fibroblasts the
H3K27me3 mark forms a broad peak centred on the first exon of
p16
INK4A; induction of senescence is associated with displacement
of PcG silencers and a profound reduction of H3K27me3 on the
chromatin associated with p16
INK4A exon 1 [40,44,45,46].
We hypothesised that the up-regulation of p16
INK4A transcrip-
tion in the absence of functional EBNA3C might result from loss of
PcG-mediated repression. Therefore ChIP analyses were per-
formed to assess the level of H3K27me3 in the p16
INK4A locus (see
schematic in Figure 5A) in LCL 3CHT cultured with and without
HT. Upon EBNA3C inactivation by the removal of HT,
Figure 3. Repression of p16
INK4A following reactivation of EBNA3C. (A) After 14 days without HT (0), total RNA was extracted from aliquots
from two LCL 3CHT populations (-A and -C). HT was re-added to the remaining cells and further RNA samples were taken at the times indicated. Real
time quantitative RT-PCR (qRT-PCR) was performed to quantify CDKN2A transcripts. The histogram corresponds to CDKN2A mRNA relative to that in
control cycling populations of each LCL 3CHT. (B) As in (A) but using a p16
INK4A-specific qPCR. (C) & (D) Similar assays to those described in (A) and (B)
after 33 days without HT. (E) Western blots – probed with a p16
INK4A-specific MAb – of protein extracts from LCL 3CHT-C cells to which HT was re-
added after 14 or 33 days in its absence (014 and 033 respectively). The control (ctrl) is LCL 3CHT-C cells continuously cultured in medium with HT.
doi:10.1371/journal.ppat.1000951.g003
Figure 4. Inactivation of EBNA3C and accumulation of p16
INK4A
leads to de-phosphorylation of Rb, reduced expression of
p107 and an increase in p130; activation of EBNA3C reverses
these processes. (A) Western blot analyses of three LCL 3CHT lines
performed on whole cell lysates from cells cultured with HT (+) without
HT for 26 days (2). As the amount of EBNA3C protein reduces (and is
inactivated) and p16
INK4A accumulates, so hyperphosphorylated Rb
(ppRb) protein disappears and only hypophosphorylated Rb (pRb) is
detected. The levels of E2F1 and c-tubulin (c-tub) remain unchanged
irrespective of the culture conditions. (B) Western blot analysis of
extracts from cells after re-addition of HT to cultures starved of HT for
either 14 or 33 days (014 and 033 respectively). A pan-specific anti-Rb
MAb and phospho-specific MAb (Ser 807–811) both show an increase in
hyperphosphorylated Rb (ppRb) after HT was added. After 12–16 days
the degree of phosphorylation is equivalent to that in the proliferating
control LCL 3CHT population (ctrl). As Rb becomes phosphorylated,
expression of p107 increases and expression of p130 decreases. The
level of c-tubulin (c-tub) did not alter throughout the experiments.
doi:10.1371/journal.ppat.1000951.g004
Epigenetic Repression of p16
INK4A by EBV
PLoS Pathogens | www.plospathogens.org 7 June 2010 | Volume 6 | Issue 6 | e1000951Figure 5. ChIP analysis to quantify the H3K27me3 and H3K4me3 marks on p16
INK4A exon 1 when EBNA3C is inactivated and re-
activated in LCL 3CHT. (A) Schematic of the human p16
INK4A-ARF locus showing the location of coding exons (boxes) and transcription start sites
(horizontal arrows) – not drawn to scale. The vertical (A-D) arrows refer to the approximate locations of primer pairs used for qPCR analysis of
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INK4A exon 1, as
transcription increased (Figure 5B and C). This process could be
reversed by reconstitution of functional EBNA3C after re-addition
of HT (see below). The time taken for H3K27me3 depletion
correlated with the length of time in culture without functional
EBNA3C and was consistent with the rate of p16
INK4A induction.
Equivalent results were obtained when similar ChIP experiments
were performed on an independent LCL 3CHT and using two
different sets of p16
INK4A exon 1-specific primers (Figure S2 and
data not shown).
Recently it became clear that the transcriptional status of
p16
INK4A is not determined by H3K27 tri-methylation alone, but
rather by the interplay between H3K27me3 and H3K4me3
modifications [44]. Therefore ChIP analyses were performed to
assess the quantities of both modifications at the p16
INK4A locus in
LCL 3CHT cultured with and without HT (Figures 5D and E).
EBNA3C inactivation (labelled -30 days) affected epigenetic marks
at the p16
INK4A locus in a manner consistent with transcriptional
activation; the repressive H3K27me3 mark was reduced while the
activation-related H3K4me3 increased. After EBNA3C reactiva-
tion (labelled +20 days), the epigenetic modifications at p16
INK4A
locus were apparently reversed.
Further ChIP assays were used to confirm the specificity of
p16
INK4A regulation. The quantities of H3K27me3 and H3K4me3
at p16
INK4A exon 1 (primer set C – indicated by boxes) were
compared to the quantities at various other sites in the CDKN2A
locus, including a region (site A) located 4.5kb downstream of
p14
ARF transcription start site (Figures 5A, D and E). As described
previously [45] in human primary fibroblasts H3K27me3 marks
are broadly distributed across the CDKN2A locus, peaking in exon
1, but extending into the region corresponding to A. Similarly, this
region in LCL 3CHT was associated with some degree of
H3K27me3 – particularly in cycling cells. However – whether or
not EBNA3C is active – H3K4me3 is detected on exon 1 (site C),
but at site A it is always completely absent. In parallel, ChIP
experiments were performed with an IgG antibody of the same
isotype as the anti-H3K27me3 or -H3K4me3 antibodies to assess
the level of background and no significant binding was observed at
any site (data not shown). The presence of two inversely regulated
modifications excludes the possibility that the reduction in histone
methylation is due to nucleosome re-positioning away from
p16
INK4A resulting in a reduction of the total histone H3 at the
locus.
Relatively high quantities of H3K4me3 were detected at the
p16
INK4A exon 1 (site C) compared to site A, even when EBNA3C
was active (in LCL 3CHT with HT and with HT re-added) and
therefore repressing p16
INK4A. This suggests that p16
INK4A exon 1 in
LCLs might contain a ‘bivalent’ or ‘poised’ chromatin domain
[47].
EBNA3C-mediated regulation of p16
INK4A does not
require Rb
To avoid biases due to the genetic background of a single donor,
we decided to confirm our findings using newly established LCL
3CHT lines from several different donors. It was soon noted that
one of these cell lines did not arrest after the removal of HT from
the medium. Western blotting with a pan-specific anti-Rb
antibody failed to detect Rb protein in this cell line (LCL
3CHT-E) cultured with or without HT (Figure 6A). Consistent
with this, qPCR showed that LCL 3CHT-E expressed low levels of
Rb mRNA in comparison to other LCL 3CHT lines (Figure 6B).
It is well established that functional Rb can regulate p16
INK4A
levels through a negative feedback loop and that Rb-negative
tumours (such as carcinoma of cervix) and tumour-derived cell
lines can express high levels of p16
INK4A [23,48]. However, even
in this LCL in which Rb cannot be detected, p16
INK4A was still
repressed in the presence of active EBNA3C, and this was relieved
after EBNA3C inactivation by the removal of HT (Figure 6A).
When ChIP analyses for H3K27Me3 (and H3K4Me3) marks
across the CDKN2A locus were performed on the LCL expressing
no detectable Rb (LCL 3CHT-E) similar patterns to those seen for
LCLs expressing Rb protein were seen (compare Figures 6C and
D with Figures 5D and E). That is, high levels of H3K27Me3
occupied exon 1 (site C) in the presence HT, while there were low
levels of this repressive mark in its absence. The reverse was true
for H3K4me3. This reinforces our view that the epigenetic
regulation of p16
INK4A by EBNA3C is independent of Rb
expression.
EBNA3A also contributes to the regulation of p16
INK4A
Recently EBNA3A was shown to regulate p16
INK4A in a
microarray study using EBNA3A-knockout (KO) LCLs [8]. The
efficiency with which LCLs can be established using EBNA3A-KO
is lower than with wild type virus, but by infecting peripheral
blood leukocytes (PBLs) including macrophages that transiently act
as feeder cells, we generated two independent EBNA3A-KO
LCLs.
Since EBNA3A and EBNA3C co-operate to epigenetically
regulate the cellular gene BIM in BL31 cells, we wanted to ask
whether EBNA3A might also cooperate with EBNA3C in
modifying chromatin at the p16
INK4A locus. The two EBNA3A-
KO LCL were validated by probing western blots of protein
extracts for the major latent EBV proteins; as previously described
for these knockouts in a BL background there were no consistent
differences in EBV gene expression ([37]; data not shown).
Although only two independent EBNA3A-KO lines were
investigated, further characterization showed that – consistent
with the report from Hertle and colleagues [8] – p16
INK4A protein
expression is elevated in both EBNA3A-KO LCLs relative to WT
(B95.8)-BAC infected LCL (Figure 7A).
A comparison of steady state levels of H3K27me3 and
H3K4me3 at the p16
INK4A locus revealed that in the absence of
EBNA3A, the ratio of H3K27me3 to H3K4me3 associated with
exon 1 was reversed relative to LCLs established with WT EBV
BACs (Figures 7B and C). The low level of H3K27me3 and high
level of H3K4me3 are consistent with a more transcriptionally
active locus and the higher levels of p16
INK4A protein detected in
the EBNA3A-knockout lines. This suggests that EBNA3A,
together with EBNA3C, is involved in the chromatin remodelling
of p16
INK4A.
In the EBNA3A-KO LCLs used for microarray analysis, the
level of Rb transcripts was reported to be lower than in LCLs
carrying WT EBV [8]. The two EBNA3A-KO LCLs described
here expressed similar levels of Rb to the WT EBV infected cells.
precipitated chromatin (as described in Materials and Methods). (B) ChIP analysis of H3K27me3 distribution on exon 1 (site C) of p16
INK4A. The
histogram shows a decline in H3K27me3 relative to a cycling LCL 3CHT (day 0). (C) Corresponding changes in p16
INK4A mRNA quantified by qRT-PCR.
(D) ChIP analysis of H3K27me3 distribution across the p16
INK4A-ARF locus in LCL 3CHT proliferating in the presence of HT, after 30 days without HT
and 20 days after re-adding HT. (E) ChIP analysis of H3K4me3 the p16
INK4A-ARF locus in LCL 3CHT proliferating in the presence of HT, after 30 days
without HT and 20 days after re-adding HT.
doi:10.1371/journal.ppat.1000951.g005
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form when EBNA3A was not expressed (data not shown).
LCLs expressing CtBP-binding mutants of EBNA3A and
EBNA3C grow relatively poorly and express higher than
normal levels of p16
INK4A
We showed previously that EBNA3A and EBNA3C mutants
that are unable to bind CtBP are severely impaired in their ability
to transform primary rat embryo fibroblasts in co-operation with
activated Ha-RAS [16,17]. Since this assay, in part, measures the
ability of proteins to overcome p16
INK4A-mediated premature
senescence and because CtBP is involved in the repression of
p16
INK4A in primary human fibroblasts and keratinocytes [22], it
seemed appropriate to ask whether the interaction of CtBP with
EBNAs 3A and C is necessary for the modulation of p16
INK4A
expression in LCLs.
Mutations in EBNA3A and EBNA3C that completely ablate
their capacity to bind CtBP have been described ([16,17];
schematic in Figure 8A). These mutations were serially engineered
into the B95.8 EBV-BAC creating CtBP-binding mutants of
Figure 6. EBNA3C-mediated regulation of p16
INK4A does not require Rb. (A) Western blot analysis of whole cell lysates from two LCL 3CHT (-
D and -E) cultured with (+) or without (-) HT for 26 days. Although Rb is undetectable in LCL 3CHT-E, when HT is removed from the growth medium,
EBNA3C decreases and p16
INK4A (p16) increases. E2F1 and c-tubulin (c-tub) levels do not alter. (B) Steady-state levels of Rb mRNA in LCL 3CHT-E
relative to 3 other LCL 3CHT and a WT-BAC LCL all cultured with HT, quantified by qRT-PCR. (C) ChIP analysis of H3K27Me3 distribution across the
p16
INK4A-ARF locus in LCL 3CHT-E cells (expressing little or no Rb) with HT or without HT in the growth medium. (D) ChIP analysis of H3K4me3
distribution across the p16
INK4-ARF locus essentially as described in (C).
doi:10.1371/journal.ppat.1000951.g006
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with revertant virus (Figure 8B). These viruses were used to
establish LCLs from PBL and fully validated by mutation-specific
PCR, CtBP IP and western blotting for EBV latent proteins
(Figure S3). Although latent EBV gene expression generally
appeared unaffected by these point mutations it was soon
noticeable that population growth was impaired. Limiting dilution
analysis of infected PBL was performed in an attempt to quantify
this impairment. In terms of the number of wells that contained
clumps of cells characteristic of LCL outgrowth after 40 days,
there was no substantial difference between the immortalization
efficiency of the wild-type and revertant viruses, as compared to
the CtBP mutants (data not shown). However, it was clear that the
rate of outgrowth of the CtBP mutant LCLs was considerably
slower than the wild-type LCLs. This effect is strikingly illustrated
by the image of the plate in which the LCLs were grown
(Figure 8C). Both the colour of the culture medium and the visible
cell clumps in the wells show the much more rapid growth of the
revertant LCLs as compared with the mutants. Also notable was
the tendency of the mutant EBVs to sometimes grow as a single
large clump of cells in the presence of a large number of smaller
clumps (Figure 8C, eg wells A4 and C5). This may indicate natural
selection driving phenotypic changes in the cells to allow the more
robust clones to emerge as LCLs. Even once LCLs are established,
CtBP-mutant LCLs continue to show a growth defect, exhibiting
reduced rate of population growth relative to wild-type and
revertant LCLs (Figure 8D). They also tended to have a much
lower maximum cell density, with CtBP-mutant LCLs struggling
to grow much beyond 0.7610
6 cells/ml.
When p16
INK4A transcripts and protein were quantified by
qRT-PCR and western blotting respectively (Figures 9A, B and C)
it was apparent that all the mutants express more p16
INK4A
mRNA and protein than either the WT-BAC or revertant-LCL
cells. We assume that this increase in p16
INK4A contributes to the
impaired outgrowth of the mutant-carrying LCLs.
Interaction of EBNA3A and EBNA3C with CtBP is
necessary for the chromatin remodelling associated with
the repression of p16
INK4A
CtBP has been implicated in PcG-mediated repression
[19,49,50,51] and may be directly involved in the chromatin
remodelling of p16
INK4A [22]. ChIP analysis within p16
INK4A exon 1
Figure 7. EBNA3A contributes to the regulation of p16
INK4A. (A) Western blot analysis of three LCLs established with virus derived from B95.8-
EBV BAC (WT) and two established with EBNA3A-KO recombinants. The steady state levels of p16
INK4A (p16) are elevated in the EBNA3A-KO cells
relative to the WT-EBV infected cells. It should be noted that similar results were reported using a larger panel of EBNA3A-KO LCLs [8]. An LCL 3CHT
(3CHT) with (+) or without (-) HT is shown for comparison. (B) & (C) ChIP analysis of H3K27me3 and H3K4me3 distribution on exon 1 (site C) and site
A in the p16
INK4A-ARF locus from an EBNA3A-KO LCL (3AKO) and a WT-EBV LCL (WT).
doi:10.1371/journal.ppat.1000951.g007
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reduction of the H3K27Me3 mark relative to a WT-EBV LCL.
There was generally a corresponding increase in the level of the
activation mark H3K4me3 relative to WT (Figure 10A). A
detailed comparison of a WT-BAC LCL and a revertant LCL
(rev
CtBP) with a double CtBP-mutant LCL (E3
CtBP) across the
p16
INK4A locus was also performed. The double CtBPM mutant
profile closely resembled those of LCL 3CHT cells grown without
HT and therefore lacking a functional EBNA3C. In contrast the
WT and revertant profiles – as would be expected – resembled
LCL 3CHT cultured in the presence of HT (compare Figures 10B
and C with Figures 5D and E). We conclude that the interaction of
both EBNA3A and EBNA3C with CtBP is important for EBV-
mediated chromatin remodelling and repression of p16
INK4A
during B cell transformation. This may explain why these
protein:protein interactions are particularly important for the
efficient outgrowth and establishment of LCLs.
Although the E3
CtBP LCL examined here appears to have an
active p16
INK4A locus and relatively high levels of p16
INK4A
protein, the cells are clearly capable of cell division – leading us to
suspect that some other element of the Rb-axis might be
compromised. An examination of these cells, and other CtBP-
mutant cells, showed that proliferation was probably not
completely inhibited because in both E3
CtBP and 3A
CtBP LCLs
expression of Rb is often reduced (see for example Figure S4).
Since there will be considerable selection pressure during the
establishment of an LCL, this is probably the result of uniden-
tified compensatory lesions occurring in the Rb-axis early after
infection and the outgrowth of the more robustly proliferating
clones.
Figure 8. LCLs expressing CtBP-binding mutants of EBNA3A and EBNA3C grow relatively poorly. (A) Schematic showing mutations of
CtBP-binding sites in EBNA3A and EBNA3C that were introduced into the CtBPM recombinant viruses. EBNA3C includes a single consensus PLDLS site
that was mutated to ALDAS [16]. EBNA3A includes two non-canonical CtBP-binding sites that synergise to produce very efficient binding to CtBP; the
ALDLS site was mutated to ALDAA and the VLDLS site was mutated to VLDAA [17]. (B) Schematic showing the generation of a series of CtBP-binding
mutant EBVs, by serially mutating the EBNA3 CtBP binding sites, and then reverting them, creating both single and double CtBP mutant EBVs, and a
revertant. (C) A plate of cells 40 days after infection of PBLs with 1000 rgu of virus per well. Difference in the colour of the medium and the visible
density/size of cell clumps in the wells are clear indicators that CtBP-mutant LCLs grow out more slowly than wild-type (not shown) and revertant
LCLs. This appears to be more striking in 3C
CtBP and E3
CtBP LCLs. (D) Established LCLs (approximately 3 months post-infection) were seeded at 5610
4
cells/ml and counted each day for a week. CtBP-mutants (dashed lines) grow more slowly, and/or have a lower maximum cell density than wild-type
and revertant LCLs (solid lines). Two cell lines were tested for each mutant.
doi:10.1371/journal.ppat.1000951.g008
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Here we show that EBNA3A, EBNA3C and CtBP are all
involved in the epigenetic repression of p16
INK4A expression that is
necessary for the proliferation of EBV-transformed B cells.
The CDKN2A locus in the human genome encodes two tumour
suppressor proteins – p16
INK4A and p14
ARF – that are encoded by
transcripts consisting of a unique first exon and shared second and
third exons (Figure 5A). However, the proteins are structurally
unrelated since p14
ARF utilizes an alternative reading frame to that
used for p16
INK4A [23]. The p16
INK4A promoter region is
epigenetically regulated by the interplay of repressive modifications,
eg H3K27me3, and activating trimethylation of lysine 4 at histone
H3 (H3K4me3) in humanstem cells,primaryfibroblasts and cancer
cells [44,45,52]. In stem cells H3K27me3 and H3K4me3
modifications co-localize at the p16
INK4A promoter and form what
is known as a ‘bivalent’ chromatin domain. Such domains are
thought to repress or silence genes while keeping them poised for
activation [47,53]. This epigenetic repression of the CDKN2A locus
is mediated by polycomb group proteins (PcG) which are thought to
silence or repress targetgenes through the formationof higherorder
chromatinstructures (eg chromatinlooping) and by ubiquitinylating
H2A at K119 – a histone modification that interferes with the
binding of RNA Polymerase II and transcriptional elongation
[39,54]. The H3K27me3 demethylase JMJD3 contributes to
plasticity of the p16
INK4A locus, and functions in a switch from the
repressive chromatin in response to oncogenic stress [45,46]
The data presented here have shown that compromising
EBNA3C function initiates chromatin remodelling that resets the
epigenetic status of p16
INK4A locus. In the presence of active
EBNA3C, the p16
INK4A locus displays repressive chromatin and the
locus is closed for transcription, but when EBNA3C is inactivated
the chromatin is remodelled into an active state that supports
transcription. These changes in epigenetic modifications of the
p16
INK4A locus might be a consequence of EBNA3C acting on the
p16
INK4A locus either directly or indirectly. Results of experiments
performed with EBNA3A-KO LCLs and CtBP-binding mutants of
both EBNA3A and 3C are all consistent with EBNA3A cooperating
with EBNA3C, and both interacting with CtBP in the regulation of
these epigenetic chromatin modifications of the p16
INK4A locus.
Potential mechanisms
Although at least one virus – Paramecium bursaria Chlorella virus
1 – encodes its own histone methyltransferase that catalyses the
Figure 9. Expression of p16
INK4A is increased in CtBPM LCLs relative to revertant and WT LCLs. (A)E 3
CtBP,3 A
CtBP,3 C
CtBP and two rev
CtBP
LCLs were harvested 28 days after the infection of primary B cells with the recombinant EBVs. RNA was extracted and the relative levels of CDKN2A
transcripts were quantified by qRT-PCR. (B) RNA was extracted from two established E3
CtBP LCLs, two 3A
CtBP LCLs, 3C
CtBP LCL, a revertant (rev
CtBP) and
a WT-EBV LCL. The relative levels of p16
INK4A transcripts were quantified by qRT-PCR. (C) Western blot analysis of protein extracts from two E3
CtBP
LCLs, two 3A
CtBP LCLs and a 3C
CtBP LCL all established from a single donor. A revertant (rev
CtBP) and a WT-EBV LCL are shown for comparison. Levels of
p16
INK4A (p16) are shown relative to c-tubulin (c-tub).
doi:10.1371/journal.ppat.1000951.g009
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genes [55], this is unlikely to be the case of EBNA3C or EBNA3A.
Even though the crystal structure of neither is available and their
secondary structure is difficult to predict [5], sequence homology
studies fail to identify a potential methyltransferase domain in
either EBNA3A or EBNA3C.
The consensus of opinion is that the regulation of p16
INK4A is
primarily under the control of members of the polycomb group of
proteins (PcG). As already indicated, these multi-component
repressor complexes generate histone modifications – including
H3K27me3 – that are characteristic of silent chromatin. These
marks are heritable and may affect the whole CDKN2A locus [23].
In Drosophila, repression by PcG complexes spreads from polycomb
response elements (PREs) located within a genomic regulatory
locus, but the equivalent of PREs have not been identified in
mammalian cells. The mechanism of targeting PcGs specifically to
the p16
INK4A locus is unknown and, more generally, how the DNA-
binding specificity of PcG complexes is achieved remains a key
Figure 10. The interaction of EBNA3A and EBNA3C with CtBP is necessary for the chromatin remodelling associated with the
repression of p16
INK4A. (A)&( B) ChIP analysis of H3K27me3 and H3K4me3 in p16
INK4A exon 1 (site C) performed in duplicate (assays i & ii) on an
E3
CtBP LCL, a 3A
CtBP and a 3C
CtBP. Similar analysis of a WT-EBV LCL is shown for comparison. (C)&( D) ChIP anaysis of H3K27me3 and H4Kme3
distribution across the p16
INK4A-ARF locus in an E3
CtBP LCL. Similar assays performed on revertant (rev
CtBP) and WT-EBV LCLs are shown for
comparison. The sites correspond to those shown in Figure 5A.
doi:10.1371/journal.ppat.1000951.g010
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PcG recruiting factors are sequence-specific transcription factors
or long non-coding RNAs (nc-RNAs) [40], so a major challenge
for the immediate future is to establish whether EBNAs 3A and 3C
together deregulate or interact with sequence specific transcription
factors or nc-RNAs that normally regulate p16
INK4A and/or BIM.
No consistent changes in the expression of PcG proteins or the
H3K27me3-specific demethylase JMJD3 have been identified in
LCLs expressing inactivated or mutated EBNAs 3A or 3C ([8]; our
unpublished observations). Furthermore, although it has been
shown that LMP1 is a negative regulator of p16
INK4A in fibroblasts
and epithelial cells [56,57], LMP1 expression was not reduced in
any of the mutant LCLs studied here or reported elsewhere
(Figures S1 and S3; [8,35]. We therefore do not think LMP1
signalling plays a significant role in the repression of p16
INK4A in B
cells.
Consequences of epigenetic repression in
lymphomagenesis
Epigenetic changes are by definition heritable, but not always
irreversible. Certain loci exhibit a high degree of plasticity and are
poised for rapid activation. Examples include families of
developmental genes such as those in the HOX locus and tumour
suppressor genes that become active when aberrant pro-prolifer-
ative signals are detected [23,40]. Our data suggest that the
repression of p16
INK4A locus by EBNA3C (presumably cooperating
with EBNA3A which is constitutively expressed) in the LCL
3CHT system is reversible. H3K27me3 is known to cause the local
formation of heterochromatin that is labile or readily reversible,
but this type of histone methylation can also facilitate methylation
of DNA of the same region, particularly in the development of
cancer. DNA methylation represents a more stable modification
and can ‘fix’ the repression of the locus. It has been shown that
promoter regions bound by PcG which remain largely unmethy-
lated on CpG dinucleotides in normal tissues, serve during
tumorigenesis as a map to direct DNA methylation. CpG
islands methylated de novo in cancer have often been previously
marked by the presence of PcG proteins and H3K27me3
[58,59,60,61,62,63]. We have shown previously that this is the
case for BIM in EBV-positive lymphomas [38]. It is therefore also
likely that during EBV-mediated lymphomagenesis p16
INK4A is
repressed as a result of EBNA3A/C-induced histone modifications
that then act as a focus for DNA methyltransferases to initiate the
more stable cancer-associated CpG methylation. This is certainly
consistent with the limited data on EBV-positive BL, that suggest
the p16
INK4A locus is nearly always silenced by DNA methylation of
exon 1 in tumour-derived cell lines and in many BL biopsies
[64,65].
Limitations of the conditional EBNA3C-HT system
EBNA3C is absolutely essential for the transformation of
primary B cells by EBV, therefore the successful establishment
of LCL 3CHT reassures us that EBNA3C modified by a C-
terminal fusion retains most of the functions required for
transformation. However, there appear to be at least two
limitations of the EBNA3C-HT fusion system. Firstly, even in
the presence of HT the repression of p16
INK4A is not complete. The
amount of p16
INK4A is higher than in WT-EBV LCL and is almost
equivalent to the accumulation seen in EBNA3A-KO and CtBP-
mutant LCLs (Figures 7A and 9C). The elevated levels of
p16
INK4A in LCL 3CHT, even in the presence of HT might
indicate that EBNA3C activation is compromised in a subpopu-
lation of cells and these cells exit from the cell cycle. Alternatively,
and perhaps more likely, fusion of EBNA3C with the large
estrogen receptor domain might partially inhibit EBNA3C
function in all cells in the population, even in the presence of
HT.
A second limitation to the utility of these cells for studying
EBNA3C function is the considerable delay between removing or
re-adding HT from/to the culture medium and the change in
levels of p16
INK4A. The first signs of p16
INK4A increase are seen
about 10 days after removing HT from the medium and the first
signs of p16
INK4A repression are apparent no sooner than two days
after re-addition of HT. This may be caused by the EBNA3C-HT
fusion not being quite equivalent to WT EBNA3C (as discussed
above) or could indicate that p16
INK4A is not a direct target of
EBNA3C. A similar phenomenon occurs during the induction of
p16
INK4A by activated RAS. It takes approximately 5 days to fully
activate p16
INK4A by RAS. Since such an extended timeframe is
not compatible with the signalling dynamics of the RAF-MEK-
ERK cascade, it has been suggested that mutant RAS leads to the
accumulation of intracellular stresses and subsequent activation of
p38 [23]. It is possible that EBV latent gene expression minus
EBNA3C or EBNA3A sets up some sort of dis-equilibrium that
results in intracellular stress, but preliminary data suggest that this
is not mediated by p38 activation (data not shown). Alternatively,
it has been suggested that the slow kinetics of p16
INK4A activation
might reflect the need to displace either repressive histone or
repressive PcG-mediated DNA methylation [23,60,66] and this
could be the case in B cells latently infected with EBV.
The role of CtBP
The role of CtBP in EBNA3A/3C-mediated repression of
p16
INK4A is intriguing but not yet understood. CtBP was discovered
because of its binding to adenoviral oncoprotein E1A. Binding of
E1A to CtBP antagonizes the function of CtBP, and E1A mutants
unable to bind CtBP show enhanced efficiency of transformation
[67]. In contrast, EBNA3A and EBNA3C mutants unable to bind
CtBP were less effective in transforming and immortalizing
primary rat embryo fibroblasts in cooperation with Ha-RAS
[16,17]. Furthermore we showed that Marek’s disease virus, a
herpesvirus that induces T cell lymphoma in chickens, requires its
nuclear oncoprotein MEQ to bind CtBP for tumorigenesis [68].
Consistent with the role of CtBP in rodent cell transformation by
EBNA3A and EBNA3C, LCLs produced by immortalization with
CtBP-binding mutant viruses grow out much more slowly than
WT-EBV LCLs and fail to effectively repress p16
INK4A. Taken
together the data suggest that binding of EBNA3A and EBNA3C
to CtBP augments transformation efficiency and LCL outgrowth
by aiding the establishment or maintenance of the H3K27me3
mark on p16
INK4A exon 1. CtBP-containing complexes have been
previously linked to chromatin remodelling including demethyla-
tion of H3K4, and CtBP has been shown to recruit PcG silencers
to certain genes in mammalian cells [19,50]. Although both
EBNA3A and EBNA3C can be immunoprecipitated from LCLs
with CtBP [16,17] and under standard conditions EBNA3A and
EBNA3C can be reciprocally co-precipitated (our unpublished
data) we have been unable to ChIP EBNA3A/3C-CtBP
complexes on either the p16
INK4A or BIM promoters (data not
shown). We do not know whether this is because of technical
limitations of the reagents that are available or whether these
promoters are not actually direct targets of the complexes. It may
be necessary to develop new regents to address this issue. Although
we do not yet understand this requirement for CtBP-binding, the
data are consistent with recent reports that the C-terminus of
EBNA3C – and specifically the PLDLS CtBP-binding site – is
necessary to completely rescue proliferation in Akata-derived
E3C-HT LCLs cultured without HT [69,70].
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Serendipitously an LCL 3CHT cell line with no detectable Rb
protein was produced. In this cell line, p16
INK4A was repressed in the
presence of functional EBNA3C and de-repressed after EBNA3C
inactivation. We therefore assume that regulation of p16
INK4A by
EBNA3C in LCL 3CHT is an Rb-independent phenomenon.
Repression of p16
INK4A in the Rb-negative LCL 3CHT line is unlikely
to be functionally relevant, because the main target of p16
INK4A is
absent. Since EBNA3C repressed p16
INK4A even when no additional
proliferation advantage was to be gained, this implies that repression
of p16
INK4A is a specific consequence of EBNA3C working in
collaboration with EBNA3A and CtBP. Decreased expression of Rb
protein was also seen in E3
CtBP and 3A
CtBP LCLs, (Figure S4) and
decreased Rb mRNA has been reported in EBNA3A-KO LCLs [8].
Since the absence of Rb will confer a common proliferative
advantage, it is probable that elevated p16
INK4A expression in these
various cell lines creates a strong selection pressure for the loss, or
reduced expression of Rb during transformation.
In summary, we have described a novel mechanism used by
EBV to overcome stress-induced growth arrest by preventing the
induction of p16
INK4A and, by a similar mechanism, enhance cell
survival by preventing the induction of pro-apoptotic BIM [37,38].
To our knowledge this ability to epigenetically inactivate a crucial
cell cycle inhibitor and a potent inducer of cell death makes EBV
unique among the known DNA ‘tumour viruses’ [71]. Under-
standing the precise molecular details of EBV-mediated chromatin
remodelling of p16
INK4A and the role that CtBP plays in this
process should cast new light on the nature of viral oncogenesis
and the mysteries of polycomb-mediated gene repression.
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Table S1 Gene expression qRT-PCR primer sequences.
Found at: doi:10.1371/journal.ppat.1000951.s001 (0.03 MB
DOC)
Table S2 ChIP qPCR primer sequences.
Found at: doi:10.1371/journal.ppat.1000951.s002 (0.03 MB
DOC)
Table S3 Sequence of PCR primers used to validate CtBP
mutants.
Found at: doi:10.1371/journal.ppat.1000951.s003 (0.03 MB
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Figure S1 Validation of LCL 3CHT. Western blot analysis of
latency-associated EBV proteins in representative LCL 3CHT-A
and -B cultured in the medium with HT and 26 days without HT.
LCL 3CHT-E line, with reduced Rb protein expression is
included in the panel for comparison.
Found at: doi:10.1371/journal.ppat.1000951.s004 (0.48 MB TIF)
Figure S2 Changes in H3K27me3 at p16
INK4A exon 1 in
response to activation of EBNA3C. Histogram shows the decline in
H3K27me3 in LCL 3CHT-A cultured for 35 days without HT and
H3K27me3 restoration after HT was re-added for 16 days. For
details seeFigure 5 and Materials and Methods of mainmanuscript.
Found at: doi:10.1371/journal.ppat.1000951.s005 (0.21 MB TIF)
Figure S3 Validation of CtBP mutant LCLs. (A) EBNA3s in
CtBP-mutant viruses fail to bind CtBP. Proteins were immuno-
precipitated (essentially as described in [16]) from 500 mgo f
protein extracted from BL31 cells stably infected by CtBP-mutant
or -revertant EBVs using 10 mg of a polyclonal anti-CtBP antibody
(C) and an isotype-matched control antibody (Ig). Immunoprecip-
itates and 5% of the input protein (i) were split between two gels
for western blotting with anti-EBNA3A and anti-EBNA3C. As is
apparent, the CtBP-binding mutant EBNA3s are not immuno-
precipitated by the anti-CtBP antibody, while the wild-type
protein is. The similar efficiency of the immunoprecipitation in
all cell lines was confirmed by re-probing with the anti-CtBP
antibody. (B) PCR validation of CtBP mutant LCLs. PCRs
specific to either the wild-type or mutant XLDLS motif were
performed for 30 cycles, and were positive for DNA from the
appropriate cell lines only. LCLs established from donor D1 are
shown here. Primer sequences are shown in Table S3. (C)
Western blot analysis of EBV latent proteins in CtBP-mutant
LCLs. This shows that there are no substantive differences in EBV
gene expression levels between mutant and wild-type LCLs in two
genetic backgrounds. Re-probing the western blots with anti-c-
tubulin antibody confirmed equal gel loading (data not shown).
The only consistent change is in the CtBP revertants, which
appear to have higher levels of EBNA-LP. There is a possible
tendency towards marginally higher levels of LMP1, in the CtBP
mutants, but this is not consistently observed in all CtBP mutants,
nor in all western blots on the same sample (data not shown).
Found at: doi:10.1371/journal.ppat.1000951.s006 (1.07 MB TIF)
Figure S4 (A) Western blot analysis showing the reduction of
Rb protein expression in the established E3CtBP and 3ACtBP
LCLs in comparison to revCtBP and WT LCLs (several months
post-infection and showing elevated p16INK4A levels for
comparison). (B) Steady state levels of Rb mRNA were quantified
by qRT-PCR. For details see Figure 4 in main text.
Found at: doi:10.1371/journal.ppat.1000951.s007 (0.29 MB TIF)
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